About Can-Fite
Can-Fite is a publicly listed company based in Petah Tikva (Israel) founded in 1994 by Pnina Fishman and Ilan Cohn. Small molecules are developed for autoimmune-inflammatory and cancer diseases. Can-Fite has raised $25.5 million across 20 funding rounds from investors including Chong Kun Dang Pharmaceutical, Giza Venture Capital and Yozma Group Korea. The company has 5 employees. Its chief executive, as recorded, is Pnina Fishman. Its focus areas include Diversified Pharmaceuticals and Drugs. Its legal entity in India is ΧΧ-Χ€ΧΧΧ ΧΧΧΧ€Χ¨ΧΧ ΧΧ’~Χ (U99999MH1977PLC010754).
Company details
Can-Fite was founded in 1994 and is headquartered in Petah Tikva, Israel. Operations are centered on the development of small molecule therapeutics targeting autoimmune-inflammatory diseases and cancer. Leadership is provided by co-founders Pnina Fishman as CEO and Ilan Cohn. Focus is placed on advancing drug candidates through preclinical and clinical stages in the biotechnology sector, with activities conducted primarily in Israel.
- Headquarters Petah Tikva, Israel
- Employees 5
- Founders Pnina Fishman, Ilan Cohn
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website canfite.com
- Social X Facebook
- Legal Name Can-Fite Biopharma Ltd.
- Annual Revenue$439.01 K (USD)-44.01as on Dec 31, 2025
- Net Profit-$10.63 M (USD)-16.21as on Dec 31, 2025
- EBITDA-$10.74 M (USD)-13.86as on Dec 31, 2025
- Total Equity Funding$25.5M (USD)
in 20 rounds
- Latest Funding Round$8.31M (USD), Post-IPO
Sep 2026
- InvestorsChong Kun Dang Pharmaceutical
& 3 more
- Employee Count5
Associated legal entities of Can-Fite
Can-Fite operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Funding Insights of Can-Fite
Can-Fite has successfully raised a total of $25.5M across 20 strategic funding rounds. The most recent funding activity was a Post-IPO round of $8.31 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.5M
- Total Rounds 20
- Last Round Post-IPO β $8.31M
- First Round $3.5M
(Mar 2001)
- Investors Count 4
Latest 10 of 20 funding rounds of Can-Fite with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $8.31M | Post-IPO | β | β | β |
| Dec 2021 | Post-IPO | β | β | β | |
| Aug 2021 | $10M | Post-IPO | β | β | β |
| Jul 2020 | $3.4M | Post-IPO | β | β | β |
| Jun 2020 | $8M | Post-IPO | β | β | β |
| Jan 2020 | $2.4M | Post-IPO | β | β | β |
| May 2019 | $6M | Post-IPO | β | β | β |
| Apr 2019 | $1M | Post-IPO | β | β | |
| Apr 2019 | $3.2M | Post-IPO | β | β | β |
| Jan 2019 | $2.35M | Post-IPO | β | β | β |
4 investors in total: 4 institutional.
Investors in Can-Fite
Can-Fite has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Chong Kun Dang Pharmaceutical, Giza Venture Capital and Yozma Group Korea.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm investing in seed & early stage companies in Israel & the US | gizavc.com | Tel Aviv, Israel | ||
| ascendvc.com | ||||
Traditional Korean pharma company with a portfolio of immunosuppressants, anti-cancers and antibiotics | 1941 | ckdpharm.com | Seoul, South Korea | |
Venture capital investments are directed toward multiple sectors. | korea.yozma.asia | Gangnam, South Korea |
Investor details for Can-Fite
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Can-Fite
2 people are tracked at Can-Fite (2 in leadership); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
Pnina Fishman | Co-Founder & CEO | Leadership |
Ilan Cohn | Co-Founder | Leadership |
Complete people profiles for Can-Fite
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Can-Fite
Can-Fite is a publicly listed company on the TASE with ticker symbol CANF in Israel, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Nov 2013
- Listed onNYSE: CANF
- Listed entityCan-Fite BioPharma Ltd.
- Exchange sectorHealth technology
- ISINIL0010944739
- Share price307.60 ILA (+0.46% on the day) · 2026-10-14
- Market capitalisation18,565,190.00 ILA
- EPS (diluted, trailing year)-10.01 ILA
- Volume (last session)4,500
Financials of Can-Fite
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.4M ILS | -33.9M ILS | -34.2M ILS |
| 2024 | 2.5M ILS | -29.2M ILS | -30.1M ILS |
| 2023 | 2.7M ILS | -28.1M ILS | -30.2M ILS |
| 2022 | 2.7M ILS | -34.2M ILS | -33.9M ILS |
| 2021 | 2.8M ILS | -40.8M ILS | -41.4M ILS |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for Can-Fite
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Can-Fite
4 dated milestones of Can-Fite across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Can-Fite is founded.
- Funding First funding round of $3.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $8.3M.
Web traffic of Can-Fite
The website of Can-Fite (canfite.com) receives about 4.5K visits a month and ranks #4,278,330 among all websites worldwide, #5,273 in Biotechnology and Pharmaceuticals.
- Monthly visits4.5K
▲ 17% vs previous month
- Unique visitors1.6K
per month
- Global rank#4,278,330
among all websites
- Category rank#5,273
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit2.1
- Average visit37 sec
- DevicesDesktop 44% Β· Mobile 56%
Websites whose visitors overlap most with Can-Fite. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sutrobio.com | 100% | 12.4K | #2,081,214 | View details | |
| arraybiopharma.com | 99% | View details | |||
| trimeris.com | 99% | View details | |||
| oncolys.com | 99% | 32.2K | #685,223 | View details | |
| redhillbio.com | 99% | 5.7K | #4,631,827 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 7 similar websites and full traffic analytics for Can-Fite
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Can-Fite
Complete news archive for Can-Fite
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Can-Fite
Can-Fite was founded in 1994 and raised its 1st funding round 7 years after it was founded.
Can-Fite is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
Pnina Fishman is the CEO of Can-Fite, as recorded in our data. They have also founded this company.
Can-Fite is a funded company, having raised a total of $25.5M across 20 funding rounds to date. The company's 1st funding round was a Post-IPO of $2.35M, raised on Mar 2001.
Can-Fite has 5 employees.
Annual revenue of Can-Fite is $439.01K as on Dec 31, 2025.
Can-Fite was founded in 1994 and is headquartered in Petah Tikva, Israel. Operations are centered on the development of small molecule therapeutics targeting autoimmune-inflammatory diseases and cancer. Leadership is provided by co-founders Pnina Fishman as CEO and Ilan Cohn. Focus is placed on advancing drug candidates through preclinical and clinical stages in the biotechnology sector, with activities conducted primarily in Israel.
Yes, Can-Fite is publicly traded on TASE under the ticker symbol CANF.
Can-Fite has 4 investors. Key investors include Chong Kun Dang Pharmaceutical, Giza Venture Capital, Yozma Group Korea, and Ascend Technology Ventures.
Can-Fite operates through ,.